A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

Abstract

Objective: To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight‐related risk factors in overweight and obese participants. Design and Methods: CONTRAVE Obesity Research‐II (COR‐II) was a double‐blind, placebo‐controlled study of 1,496 obese (BMI 30‐45 kg/m 2 ) or overweight (27‐45 kg/m 2 with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained‐release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks. The co‐primary endpoints were percent weight change and proportion achieving ≥5% weight loss at week 28. Results: Significantly ( P < 0.001) greater weight loss was observed with NB32 versus placebo at week 28 (−6.5% vs. −1.9%) and week 56 (−6.4% vs. −1.2%). More NB32‐treated participants ( P < 0.001) experienced ≥5% weight loss versus placebo at week 28 (55.6% vs. 17.5%) and week 56 (50.5% vs. 17.1%). NB32 produced greater improvements in various cardiometabolic risk markers, participant‐reported weight‐related quality of life, and control of eating. The most common adverse event with NB was nausea, which was generally mild to moderate and transient. NB was not associated with increased events of depression or suicidality versus placebo. Conclusion: NB represents a novel pharmacological approach to the treatment of obesity, and may become a valuable new therapeutic option.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 26

1. 1.

   Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004;291:2847-28s50.

   Not in our library10.1001/jama.291.23.2847

2. 2.

   Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352:1138-1145.

   Not in our library10.1056/nejmsr043743

3. 3.

   Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. 1998.

   Not in our library

4. 4.

   Grodstein F, Levine R, Troy L, Spencer T, Colditz GA, Stampfer MJ. Three-year follow-up of participants in a commercial weight loss program. Can you keep it off? Arch Intern Med. 1996;156:1302-1306.

   Not in our library

5. 5.

   Riddle M. Combining sulfonylureas and other oral agents. Am J Med. 2000;108(Suppl 6a):15S-22S.

   Not in our library10.1016/s0002-9343(00)00338-7

6. 6.

   Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep. 2002;4:343-349.

   Not in our library10.1007/s11906-002-0062-x

7. 7.

   Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW. Central nervous system control of food intake and body weight. Nature. 2006;443:289-295.

   Not in our library10.1038/nature05026

8. 8.

   Sinnayah P, Wallingford NM, Evans AE, Cowley MA. Bupropion and naltrexone interact synergistically to decrease food intake in mice. North American Association for the Study of Obesity Annual Scientific Meeting, New Orleans, LA. 2007.

   Not in our library

9. 9.

   Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009;17:30-39.

   Not in our library10.1038/oby.2008.461

10. 10.

    Prescribing Information: Vivitrol (naltrexone for extended-release injectable suspension). 2010.

    Not in our library

11. 11.

    Prescribing Information: Zyban (bupropion hydrochloride) sustained-release tablets. 2012;1-34.

    Not in our library

12. 12.

    Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94:4898-4906.

    Not in our library10.1210/jc.2009-1350

13. 13.

    Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595-605.

    Not in our library10.1016/s0140-6736(10)60888-4

14. 14.

    Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD Trial. Obesity (Silver Spring). 2011;19:110-120.

    Not in our library10.1038/oby.2010.147

15. 15.

    World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique. 2004;15:124-129.

    Not in our library

16. 16.

    Crosby RD, Kolotkin RL, Williams GR. An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol. 2004;57:1153-1160.

    Not in our library10.1016/j.jclinepi.2004.04.004

17. 17.

    Wilcox CS, Oskooilar N, Erickson JS, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav. 2010;35:229-234.

    Not in our library10.1016/j.addbeh.2009.10.017

18. 18.

    Rush AJ, Carmody TP, Reimitz PE. The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. International Journal of Methods in Psychiatric Research. 2000;9:45-59.

    Not in our library

19. 19.

    2009.

    Not in our library

20. 20.

    Fagard RH, Celis H, Thijs L, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51:55-61.

    Not in our library10.1161/hypertensionaha.107.100727

21. 21.

    Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-161.

    Not in our library10.1161/01.hyp.0000170138.56903.7a

22. 22.

    Volkow ND, Wise RA. How can drug addiction help us understand obesity? Nat Neurosci. 2005;8:555-560.

    Not in our library10.1038/nn1452

23. 23.

    Pelchat ML. Food cravings in young and elderly adults. Appetite. 1997;28:103-113.

    Not in our library10.1006/appe.1996.0063

24. 24.

    Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532-546.

    Not in our library10.7326/0003-4819-142-7-200504050-00012

25. 25.

    Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335:1194-1199.

    Not in our library10.1136/bmj.39385.413113.25

26. 26.

    Health I. 1998-2003.

    Not in our library

Cited by papers we hold 4

• Signaling pathways in obesity: mechanisms and therapeutic interventions · 2022
  Corrected
• Anti-obesity drug discovery: advances and challenges · 2021
  No notice
• Probiotic Mixture of Lactobacillus plantarum Strains Improves Lipid Metabolism and Gut Microbiota Structure in High Fat Diet-Fed Mice · 2020
  No notice
• Physiological adaptations to weight loss and factors favouring weight regain · 2015
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.